Trial
NCT04379518
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
National Cancer Institute (NCI); AIM ImmunoTech Inc.
Condition
Hematopoietic and Lymphoid Cell Neoplasm
Intervention
Recombinant Interferon Alfa-2b
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-13